Rohit Mehra
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (11)
FOXA1 is altered in 10 to 40% of prostate cancers, yet its oncogenic mechanisms remain uncharacterized in vivo. We developed knock-in mouse models representing distinct classes of FOXA1 mutations. Histopathological and multiomic analyses of prostate tissues and organoids revealed that Class 1 mutations, in conjunction with p53 inactivation, drive androgen-dependent adenocarcinomas through coactivation of mTORC1/2 and oncogenic AR signaling stemming from chimeric AR-half enhancers. By contrast, Class 2 mutations induce intraluminal plasticity by reprogramming differentiated luminal cells into a progenitor-like state through activation of KLF5 and AP-1 neo-enhancer circuitries, which enables enhanced survival and proliferation even under castrate androgen levels. Our findings establish FOXA1 as a multifaceted oncogene, with distinct mutational classes divergently evolving to drive prostate tumorigenesis or therapy-resistant progression.
Year:
2025
Mutational heterogeneity in mCRPC and its impact on detecting alterations using a single sample per patient. A, Schematic representation of mutation classification used in this study. Left, three metastatic sites from a single patient with tumor cells in each site. Mutations present in each cell are indicated by colors other than blue. Right, mutations alongside their classifications. Each pink circle on the right corresponds to one of the metastatic sites. A fully hatched circle indicates a mutation that is present in all the cells within the site (i.e., clonal), a partially hatched circle signifies a mutation that is present in some but not all of the cells within the site (i.e., subclonal), and a clear circle shows the absence of any mutation. B and C, Proportion of mutations in each class by each patient ( B ) and prostate cancer recurrently mutated gene ( C ). Other represents all remaining observed mutations. D, Fraction of mutations identified in each individual sample relative to all mutations for that patient in all sites, stratified by the number of sites profiled for a patient. Red dashed lines represent the average proportion of mutations detected. E, Detection rate of alterations for each gene. In this analysis, only patients with at least four sequenced tumors are assessed. The detection rate when evaluating four sites is set as a baseline of one for each gene, and the relative detection rates when fewer than four sites are evaluated. F, Impact of profiling additional tumors on cohort level observed prevalence of alteration in prostate cancer recurrently mutated genes. Only patients with three sequenced tumors were assessed. G, Schematic of the “species accumulation model” extrapolating the number of additional mutations that will be detected when another site is sequenced. The model predicts one step ahead, using all previously observed (solid) and predicted (semitransparent) new mutations. H, Validation of predictions from the model in G . The x -axis shows the observed number of mutations in four samples. Each y -axis box displays the IQR of the corresponding prediction based on the data from the first three sites. I, Results for the model in G . Observed (solid) and predicted (semitransparent) numbers of new mutations per additional site profiled. Each curve represents an individual patient. MSI, microsatellite instability. J, Proportions of mutations detected as increasing numbers of sites are evaluated. Each dot represents the percentage of mutations detected in a group of samples evaluated. The maximal number of mutations per patient corresponds to the asymptote from I .
Year:
2025
Overview of the cohort and ubiquitous alterations across metastatic tumors in mCRPC. A, Overview of the cohort by number of patients and samples obtained from each tissue. B, Patients and their corresponding sequenced tissue sites. Some of the patients might have multiple tumors from the same site. The “other” category includes tissues for which fewer than six tumors are obtained. C, Alteration landscape of the cohort. Likely driver genes, which are commonly altered in prostate cancer and altered at least once in this cohort, are included. LOH is only shown when it is accompanied by a mutation. D, Proportion of patients with alterations in genes recurrently altered in prostate cancer (alterations shown in C ). Among CNV alterations, only homozygous deletions and amplifications have been considered. E and F, Proportion of mutations classified as present and clonal in all sites as a function of the number of sites evaluated. E, All patients. F, Patients with at least four sites sequenced. Significance based on the Wilcoxon rank-sum test. G, CCF of mutations in prostate cancer recurrently mutated genes compared with all other detected mutations. Amp, amplification; Avg, average; del, deletion; met, metastasis, Non-Syn, nonsynonymous.
Year:
2025
Lethal prostate cancer has passed through at least two evolutionary bottlenecks: acquisition of metastatic potential and development of castration resistance. A better understanding of how this affects genetic heterogeneity across metastatic sites is needed to develop strategies to block metastatic spread and to overcome resistance. By leveraging deep whole-exome sequencing of 93 tumors from 26 patients, we examined patterns of metastatic dissemination and clonal evolution of prostate cancer. Phylogenetic reconstruction and mathematical modeling enabled quantification of the number of mutations and clones in the cancer ecosystem and characterization of each patient’s disease as an evolutionary process. Although mutations of the earliest pathogenic genetic drivers of prostate cancer were truncal, most other likely passenger mutations, copy-number alterations, and clones arose after the cancer had spread and were confined to individual metastatic sites because of polyclonal and polyphyletic seeding. Single-tissue sequencing tended to overestimate mutation clonality and, apart from truncal drivers, underestimate mutation rates for both individual patients and cohorts. This study highlights the independent evolution of metastatic lesions, which has implications for diagnostic and targeted therapy strategies. Significance: Genomic analysis of a multisite metastatic prostate cancer cohort reveals patterns of clonal heterogeneity, dissemination, and evolution, highlighting the need to evaluate multiple samples to fully characterize the clonal architecture of tumors. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI .
Year:
2025
Heterogeneity of recurrent prostate cancer CN alterations across metastatic sites. A, Top, heterogeneity in tumor ploidy across metastatic sites. Bottom, proportion of patients with truncal, heterogeneous, or no observed WGD events. B, Cohort-wide frequency of CN gains (red) and losses (blue). C, Proportion of patients with losses (left) and gains (right) on recurrently deleted and amplified regions in mCRPC. Shading indicates truncal (dark) and heterogeneous observations (per-patient). D, Heterogeneity of AR CN and mutation status across metastatic sites. Blue, presence of AR mutations. Absolute copy estimates are capped at 35. WT, wild-type. E, Increase in the detection rate of CN losses as a function of the number of sites sampled. Select loci recurrently altered in prostate cancer are highlighted. F, Increase in the detection rate of CN losses as a function of the number of sites sampled. Select loci recurrently altered in prostate cancer are highlighted.
Year:
2025
Patterns of clonal evolution and metastatic dissemination in mCRPC. A, Analytic workflow for clonal reconstruction, phylogenetic inference, and analysis of metastatic seeding patterns. Each point represents a mutation. B, Distribution of CCFs (density) within clone types stratified by position in the phylogenetic tree (trunk, branch, and leaf). C, Proportion of clone types by patient. This plot excludes the clones not placed in the trees. D, Proportion of clone types by recurrently mutated genes. This plot excludes the clones not placed in the trees. E, Total number of detected clones as a function of the number of sites profiled. Each colored curve corresponds to an individual patient. MSI, microsatellite instability. F, Number of patients density ( y -axis) compared with the average number of leaf clones they harbor. Light green, predicted number; dark green, actual number of leaf clones. G, Proportion of clones detected as increasing numbers of sites are evaluated. The maximal number of clones per-patient corresponds to the asymptote from E . H, Proportion of clones detected as truncal ( y -axis) per different number of evaluated sites ( x -axis). I and J, Classification of clonal phylogenetic trees based on ancestral relationships between seeding clones. Bolded edges indicate that the descendant clone seeded a new site. Arrows, parallel seeding (bifurcation). K and L, Juxtaposition of clonal phylogenetic trees (left) and clonal migration diagrams (right) for two index cases: WA_22 ( K ) and WA_32 ( L ). Clone colors are matched between trees and diagrams. SNV, single-nucleotide variants.
Year:
2025
Early metastatic dissemination in a case of mCRPC with heterogeneous NE differentiation. A, Overlap of mutations detected in each sequenced site of WA_24. Red color gradient indicates the fraction of all mutations in each intersection. B, Tally of mutations classified according to clonality and distribution (see Fig. 2A ). C, Genome-wide CN profiles of normalized log 2 (tumor/normal) coverage ratios across samples from WA_24 (black, diploid; red, gain; blue, loss; and green, LOH). Two representative regions were selected to illustrate shared LOH segments. D, Integrated summary of genetic drivers, gene expression, shared mutations, and notable LOH regions in WA_24 samples. SQ, squamous. E, Results of permutation testing comparing the observed number of genes within regions of shared LOH in WA_24 (red dashed lines) with a distribution based on the null model (histogram). F, Morphologic heterogeneity and spectrum in WA_24 at different sites with available formalin-fixed, paraffin-embedded slides. Left, mixed classical acinar and organoid pattern in the lung. Middle, small cell NE carcinoma–like pattern in the liver. Right, small cell NE carcinoma–like pattern in the prostate. G, Expression of marker genes for molecular subtype mCRPC as defined by Labrecque and colleagues ( 62 ). H, Parsimonious evolutionary model reflecting the similarity of genetic, phenotypic, and histologic features across tumor sites for patient WA_24.
Year:
2025
Lineage plasticity and histologic transformation from prostate adenocarcinoma to neuroendocrine (NE) prostate cancer (NEPC) occur in up to 15% to 20% of patients with castration-resistant prostate cancer (CRPC) as a mechanism of treatment resistance and are associated with aggressive disease and poor prognosis. NEPC tumors typically display small cell carcinoma morphology with loss of androgen receptor (AR) expression and gain of NE lineage markers. However, there is a spectrum of phenotypes that are observed during the lineage plasticity process, and the clinical significance of mixed histologies or those that co-express AR and NE markers or lack all markers is not well defined. Translational research studies investigating NEPC have used variable definitions, making clinical trial design challenging. In this manuscript, we discuss the diagnostic workup of metastatic biopsies to help guide the reproducible classification of phenotypic CRPC subtypes. We recommend classifying CRPC tumors based on histomorphology (adenocarcinoma, small cell carcinoma, poorly differentiated carcinoma, other morphologic variant, or mixed morphology) and IHC markers with a priority for AR, NK3 homeobox 1, insulinoma-associated protein 1, synaptophysin, and cell proliferation based on Ki-67 positivity, with additional markers to be considered based on the clinical context. Ultimately, a unified workup of metastatic CRPC biopsies can improve clinical trial design and eventually practice.
Year:
2025
Leukocyte common antigen (LCA), or CD45, is classically thought of as a leukocyte-exclusive protein, and as such, CD45 immunohistochemistry (IHC) is often used as a key differentiator between non-Hodgkin lymphomas (NHLs) and morphologically similar neuroendocrine neoplasms (NENs). Herein, we report our experience regarding aberrant CD45 immunoreactivity in a series of NENs. A natural language search was used to retrieve desired archival patient files. All prior NENs which had a positive neuroendocrine diagnosis or IHC results (synaptophysin, chromogranin, CD56, and/or neuron-specific enolase), as well as CD45 staining performed, were reviewed for possible CD45 positivity ( n = 686). Among these 686 NENs, 10 were aberrantly positive for CD45 staining. CD45 showed nuclear, cytoplasmic, and/or membranous staining in tumor cells. The significance of such staining is unclear. Albeit for a minority of patients, pathologists should be aware that NENs may aberrantly stain with CD45 and thereby pose a diagnostic pitfall. Therefore, broadening routine IHC panels is recommended to differentiate NENs more clearly from NHLs.
Year:
2024
Alveolar soft-part sarcoma (ASPS) is a rare soft tissue tumor with a broad morphologic differential diagnosis. While histology and immunohistochemistry can be suggestive, diagnosis often requires exclusion of other entities followed by confirmatory molecular analysis for its characteristic ASPSCR1-TFE3 fusion. Current stain-based biomarkers (such as immunohistochemistry for cathepsin K and TFE3) show relatively high sensitivity but may lack specificity, often showing staining in multiple other entities under diagnostic consideration. Given the discovery of RNA in situ hybridization (RNA-ISH) for TRIM63 as a sensitive and specific marker of MiTF-family aberration renal cell carcinomas, we sought to evaluate its utility in the workup of ASPS. TRIM63 RNA-ISH demonstrated high levels (H-score greater than 200) of expression in 19/20 (95%) cases of ASPS (average H-score 330) and was weak or negative in cases of paraganglioma, clear cell sarcoma, rhabdomyosarcoma, malignant epithelioid hemangioendothelioma, as well as hepatocellular and adrenal cortical carcinomas. Staining was also identified in tumors with known subsets characterized by TFE3 alterations such as perivascular epithelioid cell neoplasm (PEComa, average H-score 228), while tumors known to exhibit overexpression of TFE3 protein without cytogenetic alterations, such as melanoma and granular cell tumor, generally showed less TRIM63 ISH staining (average H-scores 147 and 96, respectively). Quantitative assessment of TRIM63 staining by RNA-ISH is potentially a helpful biomarker for tumors with molecular TFE3 alterations such as ASPS.
Year:
2024
Year:
2022
Collaborators (15)
Yuping Zhang
Research Assistant Professor
University of Michigan
Arul M Chinnaiyan
University of Michigan
Rahul Mannan
Assistant Research Professor & Director Histology Lab
University of Michigan
Tamara L. Lotan
Professor
Johns Hopkins University
Jiaoti Huang
Professor and Chairman
Duke Medicine
Massimo Loda
Chair
Weill Cornell Medical College
Lawrence True
Professor
University of Washington
Tao Huang
University of Michigan
Michael Haffner
Fred Hutchinson Cancer Research Center
Chien-Kuang Ding
Assistant Professor
University of California, San Francisco
Abhijit Parolia
Research Investigator (Jr. Faculty)
University of Michigan
Mark A. Rubin
Professor
University of Bern
Peter S. Nelson
Fred Hutchinson Cancer Research Center
Rahul Aggarwal
University of California
Sandra Carson
Weill Cornell Medicine
Make your next move.
Prepare your application
Review drafts before you send them.